Citations Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

Eissa, Nermin, Mohammed Al-Houqani, Adel Sadeq, Shreesh K. Ojha, Astrid Sasse, and Bassem Sadek. "Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder." Frontiers in neuroscience 12 (2018): 304.

Chang, Chun-Hung, Hsien-Yuan Lane, Ping-Tao Tseng, Shaw-Ji Chen, Chieh-Yu Liu, and Chieh-Hsin Lin. "Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials." Journal of Psychopharmacology 33, no. 4 (2019): 436-448.

Hsu, Mei-Chi, and Wen-Chen Ouyang. "Effects of integrated violence intervention on alexithymia, cognitive, and neurocognitive features of violence in schizophrenia: a randomized controlled trial." Brain sciences 11, no. 7 (2021): 837.

Miller, Brian J., and David R. Goldsmith. "Towards an immunophenotype of schizophrenia: progress, potential mechanisms, and future directions." Neuropsychopharmacology 42, no. 1 (2017): 299-317.

Smith, Conor C., Stella C. Martin, Kavitha Sugunan, Shelley J. Russek, Terrell T. Gibbs, and David H. Farb. "A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation." Molecular pharmacology 86, no. 4 (2014): 390-398.

Eckfeld, Ariel Jenys. Neurocognitive and Social Cognitive Impairments in Early-Onset Psychosis and At-Risk Youth: Implications for Intervention Strategies. University of California, Los Angeles, 2017.

Sommer, Iris E., Carrie E. Bearden, Edwin Van Dellen, Elemi J. Breetvelt, Sasja N. Duijff, Kim Maijer, Therese Van Amelsvoort et al. "Early interventions in risk groups for schizophrenia: what are we waiting for?." npj Schizophrenia 2, no. 1 (2016): 1-9.

Leweke, F. Markus, Juliane K. Mueller, Bettina Lange, Stefan Fritze, Cristina E. Topor, Dagmar Koethe, and Cathrin Rohleder. "Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention." CNS drugs 32, no. 7 (2018): 605-619.

de Bartolomeis, Andrea, Gianmarco Latte, Carmine Tomasetti, and Felice Iasevoli. "Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches." Molecular neurobiology 49, no. 1 (2014): 484-511.

Schverer, Marina, Laurence Lanfumey, Etienne-Emile Baulieu, Nicolas Froger, and Isabelle Villey. "Neurosteroids: non-genomic pathways in neuroplasticity and involvement in neurological diseases." Pharmacology & therapeutics 191 (2018): 190-206.

Sadek, Bassem, Ali Saad, Adel Sadeq, Fakhreya Jalal, and Holger Stark. "Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases." Behavioural brain research 312 (2016): 415-430.

Avramopoulos, Dimitrios, Brad D. Pearce, John McGrath, Paula Wolyniec, Ruihua Wang, Nicole Eckart, Alexandros Hatzimanolis et al. "Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation." PloS one 10, no. 3 (2015): e0116696.

Campellone, Timothy Ryan. Using outcomes to inform social decision-making in schizophrenia: Implications for motivation and functioning. University of California, Berkeley, 2016.

Frydecka, Dorota, B?a?ej Misiak, Edyta Pawlak-Adamska, Lidia Karabon, Anna Tomkiewicz, Pawe? Sedlaczek, Andrzej Kiejna, and Jan Aleksander Besz?ej. "Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation." European archives of psychiatry and clinical neuroscience 265, no. 6 (2015): 449-459.

Bartzokis, George, Po H. Lu, Chetan P. Amar, Erika P. Raven, Nicole R. Detore, Lori L. Altshuler, Jim Mintz et al. "Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory." Schizophrenia research 132, no. 1 (2011): 35-41.

Ezeoke, Amaka, Andrew Mellor, Peter Buckley, and Brian Miller. "A systematic, quantitative review of blood autoantibodies in schizophrenia." Schizophrenia research 150, no. 1 (2013): 245-251.

Chouinard, Guy, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, and Masaomi Iyo. "Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy." Psychotherapy and Psychosomatics 86, no. 4 (2017): 189-219.

Hartwig, Fernando Pires, Maria Carolina Borges, Bernardo Lessa Horta, Jack Bowden, and George Davey Smith. "Inflammatory biomarkers and risk of schizophrenia: a 2-sample mendelian randomization study." JAMA psychiatry 74, no. 12 (2017): 1226-1233.

Cai, HuaLin, Ting Cao, Xiang Zhou, and Jeffrey K. Yao. "Neurosteroids in schizophrenia: pathogenic and therapeutic implications." Frontiers in psychiatry 9 (2018): 73.

Bartzokis, George. "Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments." Neuropharmacology 62, no. 7 (2012): 2137-2153.